Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma in HER2-enriched Early Breast Cancer
NCT04817540Phase 2Recruiting
- Sponsor
- Gangnam Severance Hospital
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by Gangnam Severance Hospital. Started Sep 2021; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04817540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817540.